{"analyses":[{"ciLowerLimit":"95.4","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"126.7","groupDescription":"Avelumab was the Reference treatment and Avelumab + PLD was the Test treatment","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio (Test/Reference, %)","paramValue":"110"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"89","value":"21.1"},{"groupId":"OG001","spread":"74","value":"23.19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"139"}],"units":"Participants"}],"description":"Ctrough was defined as predose concentration during multiple dosing, and can be observed directly from data.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK parameter analysis set was defined as participants in the safety analysis set who had at least 1 post-dose concentration measurement above the lower limit of quantitation (LLQ) for avelumab.","reportingStatus":"POSTED","timeFrame":"At predose (0 H) on Cycle 2 Day 1","title":"Serum Trough Concentration (Ctrough) For Avelumab Following Cycle 2 Day 1 Pegylated Liposomal Doxorubicin (PLD) Dose","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (mcg/mL)"}